



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, May 4, 2023

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Attached is the press release that Pharma Mar, S.A. will distribute to the media informing of the recruitment of the first patient in a new Phase I clinical trial for the treatment of patients with different types of solid tumors with its new molecule of marine origin: PM54.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com



PharmaMar launches clinical trial on solid tumors with its new molecule PM54

Madrid, May 4th, 2023. – PharmaMar (MSE:PHM) has announced today the recruitment of the first patient in a new Phase I clinical trial for the treatment of patients with different types of solid tumors with its new molecule of marine origin: PM54.

This is the first-in-human (FIH) clinical trial with this new compound that is being carried out in hospitals in Spain, other European countries and the United States. This clinical trial aims to find the recommended dose of the treatment.

This new molecule has been tested in the laboratory, both in cell cultures, *in vitro*, and *in vivo*. In both cases, PharmaMar's new compound showed promising anti-tumor activity in a wide variety of tumor types.

PM54 is the second PharmaMar compound to enter into the clinical development stage in the last few months after PM534, which FIH phase I trial was initiated in December 2022.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation. PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbnectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbnectedin, ecubectedin, PM534 and



PM54. It also has a preclinical and clinical program in virology. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com